Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DSYN57
|
|||
| Drug Name |
CAP-100
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Clinical trial | [1] | |
| Company |
Catapult Therapeutics Lelystad, The Netherlands
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-C chemokine receptor type 7 (CCR7) | Target Info | Antagonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04704323) An Open Label Phase Ia/b Dose Escalation Followed by Dose Expansion Safety and Tolerability Trial of CAP-100, a Humanized C-C-chemokine Receptor 7 Antibody, Administered as Monotherapy in Subjects With r/r Chronic Lymphocytic Leukemia. U.S.National Institutes of Health. | |||
| REF 2 | Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody. Cancer Immunol Immunother. 2022 Mar;71(3):627-636. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.